145 related articles for article (PubMed ID: 26307642)
1. New Insights Into Nonadherence With Adjuvant Endocrine Therapy Among Young Women With Breast Cancer.
Rosenberg SM; Partridge AH
J Natl Cancer Inst; 2015 Oct; 107(10):. PubMed ID: 26307642
[No Abstract] [Full Text] [Related]
2. Caring for the breast cancer survivor.
Abdel-Razeq H
Am J Med; 2011 Feb; 124(2):e11; author reply e13. PubMed ID: 21295181
[No Abstract] [Full Text] [Related]
3. Impact of Fertility Concerns on Tamoxifen Initiation and Persistence.
Llarena NC; Estevez SL; Tucker SL; Jeruss JS
J Natl Cancer Inst; 2015 Oct; 107(10):. PubMed ID: 26307641
[TBL] [Abstract][Full Text] [Related]
4. Tamoxifen and the factor V Leiden mutation.
Cuzick J
J Natl Cancer Inst; 2010 Jul; 102(13):918-9. PubMed ID: 20554943
[No Abstract] [Full Text] [Related]
5. Current limits of knowledge in adjuvant and neoadjuvant endocrine therapy of breast cancer: the need for more clinical research.
Hayward RL; Dixon JM
Surg Oncol; 2003 Dec; 12(4):289-304. PubMed ID: 14998569
[TBL] [Abstract][Full Text] [Related]
6. [The Oxford meta-analysis of 2000: reflections and comments].
Mustacchi G
Tumori; 2005; 91(5):1-9. PubMed ID: 16459647
[No Abstract] [Full Text] [Related]
7. Tamoxifen side effects may be attributable to other causes.
Jones J
J Natl Cancer Inst; 2001 Jan; 93(1):11-2. PubMed ID: 11136833
[No Abstract] [Full Text] [Related]
8. Death due to liver failure during endocrine therapy for premenopausal breast cancer.
Rabaglio M; Ruepp B;
Acta Oncol; 2010 Aug; 49(6):874-6. PubMed ID: 20482225
[No Abstract] [Full Text] [Related]
9. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
Gradishar WJ
Oncology; 2005; 69(1):1-9. PubMed ID: 16088229
[TBL] [Abstract][Full Text] [Related]
10. More treatment options for women with hormone receptor-positive breast cancer: guideline update, studies lead to advances in care.
Printz C
Cancer; 2014 Oct; 120(19):2939-40. PubMed ID: 25241884
[No Abstract] [Full Text] [Related]
11. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.
Jankowitz RC; McGuire KP; Davidson NE
Breast; 2013 Aug; 22 Suppl 2():S165-70. PubMed ID: 24074781
[TBL] [Abstract][Full Text] [Related]
12. [The optimal duration of adjuvant therapy in breast cancer: what kind of evidence? Hormone therapy: what kind of evidence?].
Angiolini C
Suppl Tumori; 2004; 3(4):S75-6. PubMed ID: 15206219
[No Abstract] [Full Text] [Related]
13. [Risk of endometrial hyperplasia and carcinoma in breast cancer patients receiving adjuvant tamoxifen].
Semiglazov VF; Maksimov SIa; Bulgatova EA; Meshkova IE; Chepik OF; Berstein LM
Vopr Onkol; 2003; 49(2):198-204. PubMed ID: 12785205
[TBL] [Abstract][Full Text] [Related]
14. [Some specifics of tamoxifen's effect on the endometrium in menopausal cancer patients].
Ashtrafian LA; Antonova IB; Chazova NL; Motskobili TA; Babaeva NA; Al'ditskiĭ IA
Vopr Onkol; 2005; 51(2):200-5. PubMed ID: 16223001
[TBL] [Abstract][Full Text] [Related]
15. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study.
Swerdlow AJ; Jones ME;
J Natl Cancer Inst; 2005 Mar; 97(5):375-84. PubMed ID: 15741574
[TBL] [Abstract][Full Text] [Related]
16. Long-term toxicities of selective estrogen-receptor modulators and antiaromatase agents.
Mortimer JE; Urban JH
Oncology (Williston Park); 2003 May; 17(5):652-9; discussion 659, 662, 666 passim. PubMed ID: 12800793
[TBL] [Abstract][Full Text] [Related]
17. Extended adjuvant endocrine therapy in hormone-receptor positive breast cancer.
Strasser-Weippl K; Badovinac-Crnjevic T; Fan L; Goss PE
Breast; 2013 Aug; 22 Suppl 2():S171-5. PubMed ID: 24074782
[TBL] [Abstract][Full Text] [Related]
18. Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms.
Sestak I; Kealy R; Edwards R; Forbes J; Cuzick J
J Clin Oncol; 2006 Aug; 24(24):3991-6. PubMed ID: 16921052
[TBL] [Abstract][Full Text] [Related]
19. Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer.
Garber JE; Halabi S; Tolaney SM; Kaplan E; Archer L; Atkins JN; Edge S; Shapiro CL; Dressler L; Paskett ED; Kimmick G; Orcutt J; Scalzo A; Winer E; Levine E; Shahab N; Berliner N;
J Natl Cancer Inst; 2010 Jul; 102(13):942-9. PubMed ID: 20554945
[TBL] [Abstract][Full Text] [Related]
20. Multicenter phase II feasibility trial of high-dose tamoxifen in patients with refractory or relapsed multiple myeloma.
Decaudin D; Etienne MC; De Cremoux P; Maciorowski Z; Vantelon JM; Voog E; Urien S; Tran-Perennou C; Renée N; Vielh P; Némati F; Pouillart P
J Natl Cancer Inst; 2004 Apr; 96(8):636-7. PubMed ID: 15100346
[No Abstract] [Full Text] [Related]
[Next] [New Search]